Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator

The clinical benefit of primary prevention implantable cardioverter-defibrillator (ICD) therapy in asymptomatic patients (New York Heart Association [NYHA] functional class I) with ischemic cardiomyopathy and left ventricular dysfunction is continually disputed.

Source: Heart Rhythm - May 29, 2019 Category: Cardiology Authors: Avi Sabbag, Michael Glikson, Mahmoud Suleiman, Monther Boulos, Ilan Goldenberg, Roy Beinart, Eyal Nof Tags: Featured Article Source Type: research